These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8200216)

  • 21. Oral contraceptives and cervical cancer risk in Costa Rica. Detection bias or causal association?
    Irwin KL; Rosero-Bixby L; Oberle MW; Lee NC; Whatley AS; Fortney JA; Bonhomme MG
    JAMA; 1988 Jan; 259(1):59-64. PubMed ID: 3334773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depot medroxyprogesterone acetate and breast cancer. A review of current knowledge.
    Chilvers CE
    Drug Saf; 1996 Sep; 15(3):212-8. PubMed ID: 8879975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral contraceptives and gynecologic cancer: an update for the 1990s.
    Kaunitz AM
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1171-6. PubMed ID: 1415442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral contraceptive use and risk of invasive cervical cancer.
    Brinton LA; Reeves WC; Brenes MM; Herrero R; de Britton RC; Gaitan E; Tenorio F; Garcia M; Rawls WE
    Int J Epidemiol; 1990 Mar; 19(1):4-11. PubMed ID: 2351522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once-a-month injectable contraceptives: efficacy and reasons for discontinuation.
    Koetsawang S
    Contraception; 1994 Apr; 49(4):387-98. PubMed ID: 8013221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined oral contraceptives and risk of cervical carcinoma in situ. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Ye Z; Thomas DB; Ray RM
    Int J Epidemiol; 1995 Feb; 24(1):19-26. PubMed ID: 7797343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoplasia of the cervix uteri and contraception: a possible adverse effect of the pill.
    Vessey MP; Lawless M; McPherson K; Yeates D
    Lancet; 1983 Oct; 2(8356):930-4. PubMed ID: 6138502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
    Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
    JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.
    Orr-Walker BJ; Evans MC; Ames RW; Clearwater JM; Cundy T; Reid IR
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):615-8. PubMed ID: 10197077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK.
    Kyvernitakis I; Kostev K; Nassour T; Thomasius F; Hadji P
    Osteoporos Int; 2017 Jan; 28(1):291-297. PubMed ID: 27461017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative study of Cyclofem and depot medroxyprogesterone acetate (DMPA) effects on endometrial vasculature.
    Simbar M; Tehrani FR; Hashemi Z; Zham H; Fraser IS
    J Fam Plann Reprod Health Care; 2007 Oct; 33(4):271-6. PubMed ID: 17925114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report.
    Harkins GJ; Davis GD; Dettori J; Hibbert ML; Hoyt RA
    J Reprod Med; 1999 Mar; 44(3):309-12. PubMed ID: 10202754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancer, cervical cancer, and depot medroxyprogesterone acetate. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Lancet; 1984 Nov; 2(8413):1207-8. PubMed ID: 6150247
    [No Abstract]   [Full Text] [Related]  

  • 34. Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate.
    Bahamondes MV; Castro S; Marchi NM; Marcovici M; Andrade LA; Fernandes A; Bahamondes L
    Contraception; 2014 Aug; 90(2):117-22. PubMed ID: 24613369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin resistance parameters in users of the injectable contraceptive depot medroxyprogesterone acetate during one year of use.
    Cursino K; Sider M; Pavin EJ; dos Santos Pde N; Bahamondes L; Zantut-Wittmann DE; Fernandes A
    Eur J Contracept Reprod Health Care; 2016; 21(1):22-9. PubMed ID: 26140543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes.
    Westhoff C
    J Reprod Med; 1996 May; 41(5 Suppl):401-6. PubMed ID: 8725702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intraepithelial cervical neoplasia in women using intrauterine devices and long-acting injectable progestogens as contraceptives.
    Dabancens A; Prado R; Larraguibel R; Zañartu J
    Am J Obstet Gynecol; 1974 Aug; 119(8):1052-6. PubMed ID: 4136245
    [No Abstract]   [Full Text] [Related]  

  • 38. Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand studies.
    Skegg DC; Noonan EA; Paul C; Spears GF; Meirik O; Thomas DB
    JAMA; 1995 Mar; 273(10):799-804. PubMed ID: 7861575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depot medroxyprogesterone acetate: a risk factor for cervical stenosis after loop electrosurgical excisional procedure management of cervical intraepithelial neoplasia?
    Martirosian TE; Smith SC; Baras AS; Darracott MM
    J Low Genit Tract Dis; 2010 Jan; 14(1):37-42. PubMed ID: 20040834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased tissue inhibitor of metalloproteinase in the endometrium of women using depot medroxyprogesterone acetate: a role for altered endometrial matrix metalloproteinase/tissue inhibitor of metalloproteinase balance in the pathogenesis of abnormal uterine bleeding?
    Vincent AJ; Zhang J; Ostör A; Rogers PA; Affandi B; Kovacs G; Salamonsen LA
    Hum Reprod; 2002 May; 17(5):1189-98. PubMed ID: 11980737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.